Journals / Van Tıp Dergisi / 2014 / Cilt: 21 - Sayı: 3

The results of curative chemoradiotherapy in patients with esophageal squamous cell carcinoma

Yassı epitel hücreli özefagus kanserli hastalarda küratif kemoradyoterapi sonuçları

Pages
154–163
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Overall survival time was from 2.77 to 81.17, median follow-up time was 15.36 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Esophageal cancer is a malignancy with high incidence and mortality rates.
📊
Key Findings & Data:In this retrospective study, we aimed to evaluate esophageal cancer patients’ survival results and the effects of various prognostic factors on the patients treated with chemoradiotherapy.
💡
Conclusion & Impact:Results: Overall survival time was from 2.77 to 81.17, median follow-up time was 15.36 months.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Esophageal cancer is a malignancy with high incidence and mortality rates. In this retrospective study, we aimed to evaluate esophageal cancer patients’ survival results and the effects of various prognostic factors on the patients treated with chemoradiotherapy. Materials and Methods: In this study, curative chemoradiotherapy outcomes have been reviewed in data from 30 patients diagnosed with esophageal cancer. Results: Overall survival time was from 2.77 to 81.17, median follow-up time was 15.36 months. The median overall survival time was 16.33 months, 2- year and 3-year overall survival rate was 34.0% and 22.7% respectively. Disease-free follow-up period was from 2.53 to 81.17 months, median follow-up was 13.26 months. The median disease-free survival was 14.86 months, 2-year and 3-year have disease-free survival time was 30.5% and 22.9% respectively. Factors affecting survival in patients undergoing definitive chemotherapy 3 or more than 3 were found to be statistically significant. Conclusion: The expected survival rates of esophageal cancer results are still not in level of what we want to have. New chemotherapy agents and targeted therapies, and 4-D conformal RT and IMRT are being effectively applied, and less toxic treatments randomized studies are required to investigate.

Özet

Amaç: Özefagus kanseri insidansı ve mortalitesi yüksek olan bir malignitedir. Bu retrospektif çalışmada, kemoradyoterapi uygulanan özefagus kanseri tanılı hastaların sağkalım sonuçları ve çeşitli faktörlerin sağkalım üzerindeki etkilerinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: Bu çalışmada küratif kemoradyoterapi uygulanan 30 özefagus kanseri tanılı hastanın verileri retrospektif olarak gözden geçirilmiştir. Bulgular: Genel sağkalım için takip süresi 2.77 ay ile 81.17 ay arasında değişmekte olup, medyan takip süresi 15.36 aydır. Medyan genel sağkalım 16.33 ay olup, 2 yıllık ve 3 yıllık genel sağkalım değerleri sırasıyla %34.0 ve %22.7’dir. Hastalıksız sağkalım için takip süresi 2.53 ay ile 81.17 ay arasında değişmekte olup, medyan takip 13.26 aydır. Medyan hastalıksız sağkalım 14.86 ay olup, 2 yıllık ve 3 yıllık hastalıksız sağkalım süreleri sırasıyla %30.5 ve %22.9’dur. Sağkalımı etkileyen faktörlerden uygulanan KT kür sayısının 3 veya daha fazla olması tek değişkenli analizde istatistiksel olarak anlamlı bulundu. Sonuç: Sonuç olarak özefagus kanserlerinde sağkalım sonuçları günümüzde de yeterli ve beklenen düzeyde değildir. Yeni KT ajanları ve hedefe yönelik tedavilerle ve IMRT ve 4-D konformal RT’nin uygulanabilir olmasıyla daha az toksik ve etkili tedavilerin randomize çalışmalarla araştırılması gereklidir.

🔖

Cite This Article

NART, M., İZMİRLİ, M. (2014). The results of curative chemoradiotherapy in patients with esophageal squamous cell carcinoma. Van Tıp Dergisi, Cilt: 21 - Sayı: 3, 154–163. https://ajindex.com/articles/334108

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2):69-90
  2. Alıcı S, İzmirli M, Doğan E. Yüzüncü Yıl Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı'na başvuran kanser hastalarının epidemiyolojik değerlendirilmesi. Türk Onkoloji Dergisi 2006; 21(2):87-97
  3. Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus 2008; 21(4):322- 327
  4. Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 2005; 113(3):456-463
  5. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010;19(6):1468-1470
  6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1):11-30
  7. O'Reilly S, Forastiere AA. Is surgery necessary with multimodality treatment of oesophageal cancer. Ann Oncol 1995; 6(6):519-521
  8. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337(3):161- 167
  9. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339(27):1979- 1984
  10. Earlam R, Cunha-Melo JR. Oesophogeal squamous cell carcinoms: II. A critical view of radiotherapy. Br J Surg 1980; 67(7):457-461
  11. Forastiere AA. Treatment of locoregional esophageal cancer. Semin Oncol 1992; 19(4 Suppl 11):57-63
  12. Herscher LL, Cook JA, Pacelli R, Pass HI, Russo A, Mitchell JB. Principles of chemoradiation: theoretical and practical considerations. Oncology (Williston Park) 1999; 13(10 Suppl 5):11-22
  13. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281(17):1623-1627
  14. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326(24):1593-1598